Diagnosing Heart Failure – Experience and ‘Best Pathways’

Login or register to view PDF.
Abstract

Heart failure is a clinical syndrome associated with high rates of morbidity and mortality and associated healthcare costs. The burden of heart failure is likely to increase with time, but effective treatments that improve quality of life and survival are available. Accurate and timely diagnosis is crucial to ensure patients receive appropriate treatment and avoid hospital admissions. However, diagnosing heart failure can be difficult as symptoms and signs commonly overlap with other conditions. A chest X-ray can be useful to identify evidence of heart failure or other lung pathology; however, a normal result does not rule out a diagnosis of heart failure. An electrocardiogram (ECG) is often abnormal in patients with heart failure, although up to 10% of patients may have a normal ECG. Natriuretic peptides are a useful biomarker for heart failure and a negative result can rule out the diagnosis. This can be helpful in determining who should be referred for echocardiogram. A new clinical-decision rule (CDR) could help clinicians to achieve a more timely and accurate diagnosis of heart failure.

Disclosure
Clare Taylor has no conflicts of interest to declare. Richard Hobbs receives research funding from the National Institutes of Health (NIH), the Medical Research Council (MRC), the National Institute for Health Research Health Technology Assessment (NIHR HTA) and Roche Diagnostics. He also serves as a consultant or on speaker panels or receives sponsorship from AstraZeneca, Boeringer, MSD, Pfizer, Roche, sanofi-aventis, Servier and Takeda.
Correspondence
Clare Taylor, Primary Care Clinical Sciences, School of Health and Population Sciences, Primary Care Clinical Sciences Building, University of Birmingham, B15 2TT, UK. E: c.j.taylor.1@bham.ac.uk
Received date
18 June 2010
Accepted date
16 August 2010
DOI
http://dx.doi.org/10.15420/ecr.2010.6.3.10

Heart failure is a complex clinical syndrome that results from a structural or functional cardiac abnormality. The prevalence of heart failure is likely to increase as the population ages and survival rates following myocardial infarction continue to improve.1 Morbidity and mortality rates are significant and relate to high healthcare costs in terms of hospital admissions and long-term care.2 However, evidence-based therapies such as angiotensin-converting enzyme (ACE) inhibitors3,4 and β-blockers5–7 for all stages of heart failure and spironolactone8 in severe heart failure can improve quality of life and survival; therefore, prompt and accurate diagnosis is vital to improve outcomes for patients with heart failure.

Diagnostic Accuracy

Patients with heart failure commonly present with shortness of breath, oedema or fatigue, but these symptoms can overlap with other medical conditions, making accurate diagnosis challenging.9 Heart failure is also more common in older patients with multiple morbidities, which may further complicate the clinical picture. In a large population-based study of patients diagnosed with new-onset heart failure, the median age at presentation was 76 years.10 Patients often present to primary care clinicians and there is evidence to suggest diagnosis may be inaccurate, with only 50% of patients with a clinical label of heart failure having a confirmed diagnosis after formal assessment according to diagnostic criteria.11–13 The lack of confidence of primary care physicians in establishing an accurate diagnosis, limited diagnostic provisions, concerns about use of polypharmacy in older, frail patients and poor interaction between primary and secondary care are possible barriers to accurate diagnosis and effective management.14,15

Definitions of Heart Failure

The European Society of Cardiology (ESC) has published a clear definition of heart failure that requires the presence of both symptoms and signs of heart failure and objective evidence of a structural or functional abnormality of the heart at rest. The ESC stated that ‘Heart failure is a clinical syndrome in which patients experience the following features: symptoms typical of heart failure (breathlessness at rest or on exercise, tiredness, fatigue, ankle swelling); signs typical of heart failure (tachycardia, tachypnoea, pulmonary rales, pleural effusion, raised jugular venous pressure, hepatomegaly, peripheral oedema); and objective evidence of a structural or functional abnormality of the heart at rest (cardiomegaly, third heart sound, cardiac murmurs, abnormality on echocardiogram, raised B-type natriuretic peptides [BNPs]).’16

Clinical Symptoms and Signs

Patients with heart failure often present with gradual-onset symptoms of breathlessness, fatigue and ankle swelling. A recent systematic review found that the sensitivity and specificity of clinical features of heart failure are highly variable, as shown in Table 1.25 Symptoms such as orthopnoea or added heart sounds have a high specificity, which means patients with suspected heart failure who have these symptoms are likely to have the condition. However, sensitivity for both of these symptoms is low, which means their absence does not rule out the diagnosis. Dyspnoea has a sensitivity of 87%, the highest sensitivity of the symptoms and signs examined, suggesting this is a common symptom in patients with heart failure. However, up to 13% of patients with a diagnosis of heart failure may not have these symptoms, which means a significant number may be misdiagnosed if the absence of dyspnoea is used to rule out the condition.

Chest X-ray

A chest X-ray may show features of heart failure such as an increased cardiothoracic ratio, lung interstitial oedema or bilateral pleural effusions.17 A systematic review including five studies that estimated the accuracy of an abnormal chest X-ray in detecting a diagnosis of heart failure found considerable variation between studies.24 Sensitivity was 68% (95% confidence interval [CI] 40–88%) and specificity 83% (95% CI 66–93%); therefore, an abnormal chest X-ray may be suggestive of heart failure, but a normal chest X-ray cannot rule out the diagnosis. A chest X-ray can be valuable to rule out other pathology that may be responsible for symptoms, such as breathlessness. However, common aetiological factors such as smoking are associated with cardiac and pulmonary pathology, so patients may have more than one disease as a cause for their presenting symptoms.

Electrocardiogram

Abnormalities such as left ventricular hypertrophy, evidence of previous myocardial infarction or arrhythmias may be seen on the electrocardiogram. Guidelines suggest all patients with suspected heart failure should have an electrocardiogram.16 An abnormal ECG has a relatively high sensitivity for a diagnosis of heart failure of 89% (95% CI 77–95%) but a moderate specificity of 56% (95% CI 46–66%) suggesting, that heart failure is quite unlikely in the presence of a normal ECG; however, abnormalities on ECG may be associated with a diagnosis other than heart failure. Patients may benefit from further management of abnormal ECG findings such as atrial fibrillation, where anticoagulation to prevent thromboembolic events may be indicated.

The Role of Natriuretic Peptides

Natriuretic peptides are useful biomarkers in patients with heart failure. BNP and N-terminal pro-BNP (NT-proBNP) are released by the ventricles of the heart in response to volume and pressure overload.18 BNP relaxes vascular smooth muscle to reduce ventricular preload and acts on the kidney to increase sodium excretion and induce a diuresis. NT-proBNP is an inactive fragment of the cleaved pro-BNP molecule. NT-proBNP and BNP assays have been found to be equally reliable for diagnostic use in heart failure.19
Many studies have examined the use of natriuretic peptides in clinical practice and they are recommended for use in European guidelines.16 Natriuretic peptides have a high sensitivity for heart failure, meaning a negative result makes heart failure unlikely.20 This can be useful in complex patients with several co-existing diseases to exclude heart failure as a cause of symptoms such as dyspnoea that have a wide differential diagnosis.21 If natriuretic peptide is raised, further investigation with echocardiogram is required to confirm the diagnosis. Table 2 summarises the overall accuracy of investigations for heart failure.

Echocardiogram

Echocardiogram is the investigation of choice to provide objective evidence of cardiac abnormality in order to diagnose heart failure in clinical practice.16 Echocardiogram is an ultrasound imaging technique that provides information about the structure and function of the walls and valves of the heart. Doppler imaging can also be used to provide further information about blood flow and tissue characteristics. Echocardiogram can be useful to distinguish between heart failure due to systolic dysfunction and heart failure with normal ejection fraction (HFNEF). The degree of left ventricular impairment as measured by EF can be a useful prognostic indicator.22 Other causes of heart failure such as significant valvular disease or cardiomyopathy can also be identified on echocardiogram.23
Although the standard clinical investigation, echocardiography is not a gold standard test and suffers as a semi-qualitative test with potential operator variation. In practice, heart failure diagnosis requires clinical interpretation of all the clinical features and tests for definitive allocation of cases.

Heart Failure with Normal Ejection Fraction

HFNEF occurs when symptoms and signs of the syndrome of heart failure are accompanied by a normal EF and objective evidence of abnormal cardiac function during diastole.24 The ESC has produced guidelines that describe in detail how to diagnose HFNEF using a combination of clinical symptoms and signs, echocardiogram with tissue Doppler and natriuretic peptides.25 Recent clinical trials in terms of the treatment of patients with HFNEF with treatments used in heart failure with reduced EF have shown disappointing results; however, non-adherence to diagnostic guidelines may have led to some of these studies being underpowered, highlighting the importance of consistent and accurate diagnosis.26

Advances in Diagnostic Triaging

A clinical-decision rule (CDR) using clinical features and a blood test for natriuretic peptide has been derived that could optimise appropriate referral for echocardiography.27 The CDR was derived following a meta-analysis using individual patient data that determined the sensitivity and specificity of clinical features associated with heart failure. Patients presenting with symptoms such as breathlessness, fatigue or ankle swelling where a diagnosis of heart failure is suspected should be referred directly to echocardiography if they have any of the following three features: male with ankle oedema or history of myocardial infarction or basal crepitations (MICE). If none of these features is present, patients should undergo BNP or NT-proBNP testing. Referral for echocardiogram is based on the natriuretic test result, as stated below.

  • Female without ankle oedema – refer if BNP >210–360pg/ml depending on local availability of echocardiography (or NT-proBNP >620–1,060pg/ml).
  • Male without ankle oedema – refer if BNP >130–220pg/ml (or NT-proBNP >390–660pg/ml).
  • Female with ankle oedema – refer if BNP >100–180pg/ml (or NT-proBNP >190–520pg/ml).

The CDR is currently being prospectively validated in a primary care population presenting with new-onset symptoms of breathlessness, fatigue or ankle swelling where a diagnosis of heart failure is suspected.

Conclusion

Heart failure poses a significant diagnostic challenge for clinicians due the non-specific nature of clinical features in patients who are often elderly with multiple morbidities. A careful clinical assessment followed by appropriate and timely investigation is required to ensure patients receive an accurate diagnosis. Patients with heart failure can then receive optimal evidence-based treatments that will improve both prognosis and quality of life.

References
  1. Barker WH, Mullooly JP, Getchell W, Changing incidence and survival for heart failure in a well-defined older population, 1970–1974 and 1990–1994, Circulation, 2006;113(6):799–805.
    Crossref | PubMed
  2. Stewart S, Jenkins A, Buchan S, et al., The current cost of heart failure to the National Health Service in the UK, Eur J Heart Fail, 2002;4(3):361–71.
    Crossref | PubMed
  3. Pfeffer MA, Braunwald E, Moye LA, et al., for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial, N Engl J Med, 1992;327:669–77.
    Crossref | PubMed
  4. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators, N Engl J Med, 1991;325(5):293–302.
    Crossref | PubMed
  5. Eichhorn EJ, Bristow MR, The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial, Curr Control Trials Cardiovasc Med, 2001;2(1):20–3.
    Crossref | PubMed
  6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet, 1999;353(9146):9–13.
    Crossref | PubMed
  7. Hjalmarson A, Goldstein S, Fagerberg B, et al., Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group, JAMA, 2000;283(10):1295–1302.
    Crossref | PubMed
  8. Pitt B, Zannad F, Remme WJ, et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 1999;341(10):709–17.
    Crossref | PubMed
  9. Dickstein K, Diagnosis and assessment of the heart failure patient: the cornerstone of effective management, Eur J Heart Fail, 2005;7(3):303–8.
    Crossref | PubMed
  10. Cowie MR, Wood DA, Coats AJS, et al., Incidence and aetiology of heart failure: A population-based study, Eur Heart J, 1999;20:421–8.
    Crossref | PubMed
  11. Davies MK, Hobbs FDR, Davis RC, et al., Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study, Lancet, 2001;358:439–44.
    Crossref | PubMed
  12. Remes J, Miettinen H, Reuanen A, et al., Validity of clinical diagnosis of heart failure in primary health care, Eur Heart J, 1991;12;315–21.
    PubMed
  13. Hobbs FDR, Roalfe AK, Davis RC, et al., Prognosis of allcause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES), Eur Heart J, 2007;28:1128–34.
    Crossref | PubMed
  14. Fuat A, Hungin APS, Murphy JJ, et al., Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study, BMJ, 2003;326(7382):196.
    Crossref | PubMed
  15. Khunti K, Hearnshaw H, Baker R, et al., Heart failure in primary care: qualitative study of current management and perceived obstacles to evidence-based diagnosis and management by general practitioners, Eur J Heart Fail, 2002;4(6):771–7.
    Crossref | PubMed
  16. European Society of Cardiology, Heart Failure Association of the ESC (HFA), European Society of Intensive Care Medicine (ESICM), Dickstein K, Cohen-Solal A, Filippatos G, et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM), Eur J Heart Fail, 2008;10(10):933–89.
    Crossref | PubMed
  17. Fonseca C, Mota T, Morais H, et al., The value of the electrocardiogram and chest x-ray for confirming or refuting a suspected diagnosis of heart failure in the community, Eur J Heart Fail, 2004;6:807–12.
    Crossref | PubMed
  18. Levin ER, Gardner DG, Samson WK, Natriuretic peptides, New Eng J Med, 1998;339(5):321–8.
    Crossref | PubMed
  19. Hobbs FD, Davis RC, Roalfe AK, et al., Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations, Heart, 2004;90(8):866–70.
    Crossref | PubMed
  20. Hobbs FDR, Davis RC, Roalfe AK, et al., Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations, BMJ, 2002;324:1498–1500.
    Crossref | PubMed
  21. Moriates C, Maisel A, The Utility of Biomarkers in Sorting Out the Complex Patient, Am J Med, 2010;123:393–9.
    Crossref | PubMed
  22. Hobbs FD, Roalfe AK, Davis RC, et al., Prognosis of allcause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES), Eur Heart J, 2007;28(9):1128–34.
    Crossref | PubMed
  23. Vitarelli A, Tiukinhoy S, Luzio SD, et al., The role of echocardiography in the diagnosis and management of heart failure, Heart Fail Rev, 2003;8:181–9.
    Crossref | PubMed
  24. Zile MR, Brutsaert DL, New concepts in diastolic dysfunction and diastolic heart failure: Part 1, Circulation, 2002;105:1387–93.
    Crossref | PubMed
  25. Paulus WJ, Tschope C, Sanderson JE, et al., How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Scoiety of Cardiology, Eur Heart J, 2007;28:2539–50.
    Crossref | PubMed
  26. Paulus WJ, van Ballegoij JJM, Treatment of Heart Failure with Normal Ejection Fraction. An Inconvenient Truth!, J Am Coll Cardiol, 2010;55:526–37.
    Crossref | PubMed
  27. Mant J, Doust J, Roalfe A, et al., Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care, Heart Fail Rev, 2009;13:32.
    Crossref | PubMed